The New York City–based pharmaceutical company delivered strong financial results in 2021, with total revenue growing 9% year over year to $46.4 billion. Bristol-Myers Squibb enjoyed strong sales for drugs like Revlimid and Opdivo, used in the treatment of certain cancers; and Eliquis, an anticoagulant. Its product-development pipeline also looks healthy: In 2021, the company obtained more than 20 regulatory approvals for new medicines.
Lists ranking Bristol-Myers Squibb
World’s Most Admired Companies - 2022Just as it dominates our economy, Big Tech now dom...view in list
Latest news for Bristol-Myers Squibb
- NewslettersWhat a Bristol-Myers project to monitor off-label prescribing says about future uses of A.I.January 25, 2022 4:18 PM UTC
- ConferencesLeaders from Peloton, Chobani, and more on how brands earn their purposeOctober 13, 2021 2:15 PM UTC
- HealthBooster shots and a big jump in market value: 3 takeaways from Moderna’s Q2 earningsAugust 5, 2021 9:32 PM UTC
- TechBritish A.I. drug discovery startup Exscientia buys Austrian cancer cell screening companyJune 15, 2021 8:00 AM UTC
- HealthSeniors face steep drug costs as Congress stalls on capping Medicare out-of-pocketsDecember 28, 2020 10:00 AM UTC